
|Videos|September 10, 2019
Combinations May Be the Future in HCC
Advertisement
Key Takeaways:
Novel studies looking at combining locoregional therapies with newer immuno-oncology agents for early-stage hepatocellular carcinoma (HCC).
Evolving the treatment landscape of hepatocellular carcinoma (HCC) by moving effective systemic therapy combinations into the frontline.
Improving overall survival in patients with advanced or metastatic hepatocellular carcinoma by combining immunotherapies with tyrosine kinase inhibitors (TKIs) or novel antibodies.
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA granted priority review to sonesitatug vedotin for previously treated CLDN18.2-positive advanced gastroesophageal cancers.

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5



